Title:
COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING INDUCIBLE FUSION PROTEINS
Document Type and Number:
WIPO Patent Application WO/2019/222275
Kind Code:
A3
Abstract:
Provided herein are inducible T cell receptor (TCR) fusion proteins (TFPs) having specificity for one or more tumor cell associated antigens, T cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer, in particular for use in adoptive cell therapy.
Inventors:
BAEUERLE PATRICK (US)
GETTS DANIEL (US)
ASHMINOVA VANIA (US)
LOFGREN MICHAEL (US)
HOFMEISTER ROBERT (US)
GETTS DANIEL (US)
ASHMINOVA VANIA (US)
LOFGREN MICHAEL (US)
HOFMEISTER ROBERT (US)
Application Number:
PCT/US2019/032298
Publication Date:
August 20, 2020
Filing Date:
May 14, 2019
Export Citation:
Assignee:
TCR2 THERAPEUTICS INC (US)
International Classes:
C07K16/28; C07K16/18
Domestic Patent References:
| WO2018067993A1 | 2018-04-12 | |||
| WO2017041749A1 | 2017-03-16 | |||
| WO2017162587A1 | 2017-09-28 |
Foreign References:
| US20150087810A1 | 2015-03-26 |
Attorney, Agent or Firm:
ZHANG, Mengmeng (US)
Download PDF:
Previous Patent: COUPLING OF ION MOBILITY SPECTROMETER WITH MASS SPECTROMETER
Next Patent: PROTECTIVE COVER FOR OUTDOOR APPARATUS
Next Patent: PROTECTIVE COVER FOR OUTDOOR APPARATUS